AptaBio Therapeutics Inc. (KOSDAQ:293780)

South Korea · Delayed Price · Currency is KRW

7,460.00

-20.00 (-0.27%)

Feb 27, 2026, 3:30 PM KST

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
New Business Division - Product Sales (ODM)	1.68B	209.82M	-
New Business Division - Product Sales (ODM) Growth	701.64%	-	-
New business division - Product Sales (General)	1.56B	61.74M	48.35M
New business division - Product Sales (General) Growth	2430.95%	27.69%	-
Research and Development Department - Reagent Sales	116.39M	52.31M	-
Research and Development Department - Reagent Sales Growth	122.50%	-	-
Total	3.36B	323.87M	48.35M
Total Growth	937.76%	569.82%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
South Korea	3.36B	323.87M	48.35M
South Korea Growth	937.76%	569.80%	-
Total	3.36B	323.87M	48.35M
Total Growth	937.76%	569.80%	-

Source: S&P Global Market Intelligence.